TP53 and neoplasm: In hepatocellular carcinoma patients with urea cycle defects, the combined use of arginine restriction and GCN2 inhibition has shown significant inhibitory effects.312 Treatment with dichloroacetate (DCA) can enhance oxidative phosphorylation in p53-positive tumor cells, induce the expression of stress ligands (such as MICA/B), and strengthen the efficacy of CAR T cell or allogeneic NK cell therapy.